Table 1.
Baseline Characteristics of the Retrospective and Prospective Case Series Studies
| Clinical characteristics | Retrospective case series (n=19) | Prospective case series (n=23) |
|---|---|---|
| Men (%) | 17 (89.5) | 21 (91.3) |
| Age, y | 66.6±9.1 | 62.7±18.3 |
| Non‐ischemic | 3 (15.8) | 3 (13.0) |
| Ischemic cardiomyopathy | 15 (79.0) | 13 (56.5) |
| Cardiac sarcoid | 1 (5.3) | 1 (4.4) |
| ARVD/ARVC | … | 6 (26.1) |
| LVEF (%) | 37.8 | 34.8 |
| Heart failure (%) | 14 (73.7) | 14 (60.8) |
| ICD present | 15 (78.9) | 20 (87.0) |
| CRT‐D present | 2 (10.5) | 3 (13.0) |
| Medication (%) | ||
| Beta blocker | 13 (68.4) | 20 (87.0) |
| Amiodarone | 10 (52.6) | 10 (43.5) |
| Mexiletine | 4 (21.1) | 2 (8.7) |
ACEi indicates angiotensin‐converting enzyme inhibitors; ARVD/ARVC, arrhythmogenic right ventricular dysplasia/arrhythmogenic right ventricular cardiomyopathy; CRT‐D, cardiac resynchronization therapy defibrillator; ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; and VT, ventricular tachycardia.